Basic understanding of gonadotropin-releasing hormone-agonist triggering

被引:38
|
作者
Casper, Robert F. [1 ,2 ]
机构
[1] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Div Reprod Sci, Toronto, ON M5G 1X5, Canada
[2] Toronto Ctr Adv Reprod Technol Fertil Partners, Toronto, ON, Canada
关键词
Gonadotropin-releasing hormone (GnRH) agonist; human chorionic gonadotropin (hCG); in vitro fertilization (IVF); ovulation induction; ovarian hyperstimulation syndrome (OHSS); HUMAN CHORIONIC-GONADOTROPIN; LUTEINIZING-HORMONE; OVARIAN HYPERSTIMULATION; GNRH AGONIST; INDUCTION; SURGE; MATURATION; CYCLES; TIME;
D O I
10.1016/j.fertnstert.2014.12.129
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
A single bolus of human chorionic gonadotropin (hCG) at midcycle has been the gold standard for triggering final oocyte maturation and ovulation in assisted reproductive technology cycles. More recently, gonadotropin-releasing hormone (GnRH)-agonist (GnRH-a) triggering has been introduced. The GnRH-a trigger may allow a more physiologic surge of both luteinizing hormone (LH) and follicle-stimulating hormone, although whether the combined surge will result in improved oocyte and embryo quality remains to be seen. However, the short duration of the LH surge with the GnRH-a trigger (approximately 34 hours) has been shown to be beneficial for preventing ovarian hyperstimulation syndrome in GnRH antagonist in vitro fertilization (IVF) cycles when compared with the prolonged elevation of hCG (>= 6 days) after exposure to an hCG bolus. This review discusses the physiologic basis for the use of a GnRH-a trigger in IVF cycles. (C) 2015 by American Society for Reproductive Medicine.
引用
收藏
页码:867 / 869
页数:3
相关论文
共 50 条
  • [21] Ovarian Cyst Formation Following Gonadotropin-Releasing Hormone-Agonist Administration Decreases the Oocyte Quality in IVF Cycles
    Eryilmaz, Ozlem Gun
    Sarikaya, Esma
    Aksakal, Fatma Nur
    Hamdemir, Sevtap
    Dogan, Muammer
    Mollamahmutoglu, Leyla
    BALKAN MEDICAL JOURNAL, 2012, 29 (02) : 197 - 200
  • [22] Model of gonadotropin-releasing hormone and gonadotropin-releasing hormone complex
    Wiwanitkit, Viroj
    SEXUALITY AND DISABILITY, 2006, 24 (03) : 175 - 178
  • [23] Model of gonadotropin-releasing hormone and gonadotropin-releasing hormone complex
    Viroj Wiwanitkit
    Sexuality and Disability, 2006, 24 : 175 - 178
  • [24] Luteal phase support after gonadotropin-releasing hormone agonist triggering: does it still matter?
    Benadiva, Claudio
    Engmann, Lawrence
    FERTILITY AND STERILITY, 2018, 109 (05) : 763 - 767
  • [25] Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
    Arani, Kobra Shiasi
    Heidari, Fatemeh
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2015, 13 (03)
  • [26] INTRANASAL GONADOTROPIN-RELEASING HORMONE AGONIST AS A CONTRACEPTIVE AGENT
    BERGQUIST, C
    NILLIUS, SJ
    WIDE, L
    LANCET, 1979, 2 (8136): : 215 - 217
  • [27] GONADOTROPIN-RELEASING HORMONE AGONIST TREATMENT OF ENDOMETRIOSIS AND MYOMAS
    GIUDICE, LC
    WESTERN JOURNAL OF MEDICINE, 1990, 152 (04): : 409 - 409
  • [28] Depression in women treated with a gonadotropin-releasing hormone agonist
    Toren, P
    Dor, J
    Mester, R
    Mozes, T
    Blumensohn, R
    Rehavi, M
    Weizman, A
    BIOLOGICAL PSYCHIATRY, 1996, 39 (05) : 378 - 382
  • [29] Utilization of gonadotropin-releasing hormone agonist products in adolescents
    Woods, Corinne
    Ho, Amy
    Dutcher, Sarah K.
    Ajao, Adebola
    Hawrusik, Rebecca
    Schoeplein, Ryan
    Moeny, David
    Huang, Ting-Ying
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 319 - 320
  • [30] ENDOMETRIOSIS - TREATMENT WITH GONADOTROPIN-RELEASING HORMONE AGONIST BUSERELIN
    FRANSSEN, AMHW
    KAUER, FM
    CHADHA, DR
    ZIJLSTRA, JA
    ROLLAND, R
    FERTILITY AND STERILITY, 1989, 51 (03) : 401 - 408